17,261 trials
Idiopathic Pulmonary Fibrosis
Primary: Absolute Change From Baseline in Percent Predicted Forced Vital Capacity (FVC) at Week 52 — -5.81; -5.24; -6.31 percent predicted FVC — p== 0.6339
Malaria
Primary: Infection Success of Vector Mosquitoes — 2; 3 Participants
Leukemia · Chronic Lymphocytic Leukemia · Lymphocytic Leukemia
Primary: Participants With a Response — 0; 3 Participants
Non-Small-Cell Lung Carcinoma
Primary: The Incidence and Time to Development of Common Terminology Criteria for Adverse Events, Version 3.0 (CTCAE v3.0) Grade > 3 Treatment-related Pneumonitis (TRP) — 2; 0…
Atopic Dermatitis (AD)
Primary: Per-Participant Daily Event Rate: Serious and Non-Serious Treatment Emergent Adverse Events (TEAEs) — 0.19; 0.34 events per-participant-day — p=0.075
Glioblastoma
Primary: Objective Response Rate — 1 Participants
Prostate Cancer
Primary: Lack of Disease Progression at 12 Weeks — 14; 11 Participants
Diabetic Retinopathy
Primary: Number of Participants With Ocular and Non-Ocular Adverse Events — 11; 10; 5; 3 Participants
Glioblastoma
Primary: Adult Study: Overall Survival (OS) — 5.7; 4.6; 4.9; 9.6 months — p== 0.062
Malaria, Falciparum
Primary: Subjects Time to First Clinical Episode of P Falciparum Malaria During the Efficacy Follow-up Period Adjusted for Time at Risk - Intent to Treat (ITT) Population — 107…
Cardiomyopathy · Renal Impairment
Primary: Change in Urinary Sodium Excretion — 74.43; 29.11 MEq/min — p=0.04
Current Smoker · Former Smoker · Multiple Pulmonary Nodules
Primary: Change in the Sum of Longest Diameters of Baseline Target Nodules (Person-specific Analysis) — 0.3; -0.12 millimeter (mm)
Bullous Pemphigoid · Pemphigoid
Primary: Cessation of Blister Formation — NA days
Hepatocellular Carcinoma · Malignant Neoplasm
Primary: Recurrence-free Survival (RFS) Time — 9.5; 12 months
Relapsed Acute Myeloid Leukemia
Primary: Feasibility of a Novel Combination of Pembrolizumab and Decitabine in Relapsed/Refractory Acute Myeloid Leukemia Participants — 10 Participants